Okumura N, Gorkun O V, Lord S T
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7525, USA.
J Biol Chem. 1997 Nov 21;272(47):29596-601. doi: 10.1074/jbc.272.47.29596.
During blood coagulation, soluble fibrinogen is converted to fibrin monomers that polymerize to form an insoluble clot. Polymerization has been described as a two-step process: the formation of double-stranded protofibrils and the subsequent lateral aggregation of protofibrils into fibers. Previous studies have shown that gamma chain residues Tyr-363 and Asp-364 have a significant role in polymerization, most likely in protofibril formation. To better define the role of these residues, we synthesized three fibrinogens with single substitutions at these two positions: Tyr-363 --> Ala, Asp-364 --> Ala, and Asp-364 --> His. We found that the release of fibrinopeptides A and B was the same for these variants and normal recombinant fibrinogen, showing that all variants had normal fibrin formation. In contrast, we found that polymerization was significantly delayed for both Ala variants and was almost nonexistent for the His variant. Clottability for the Ala variants was only slightly reduced, and fibrin gels were formed. Surprisingly, clottability of the His variant was substantially reduced, and fibrin gels were not formed. Our data suggest that both protofibril formation and lateral aggregation were altered by these substitutions, indicating that the C-terminal domain of the gamma chain has a role in both polymerization steps.
在血液凝固过程中,可溶性纤维蛋白原被转化为纤维蛋白单体,这些单体聚合形成不溶性凝块。聚合过程被描述为一个两步过程:双链原纤维的形成以及随后原纤维横向聚集形成纤维。先前的研究表明,γ链残基Tyr-363和Asp-364在聚合过程中起重要作用,最有可能参与原纤维的形成。为了更好地确定这些残基的作用,我们合成了在这两个位置有单个取代的三种纤维蛋白原:Tyr-363→Ala、Asp-364→Ala和Asp-364→His。我们发现,这些变体和正常重组纤维蛋白原释放纤维蛋白肽A和B的情况相同,这表明所有变体都有正常的纤维蛋白形成。相比之下,我们发现两种Ala变体的聚合均显著延迟,而His变体几乎不存在聚合现象。Ala变体的凝血能力仅略有降低,并形成了纤维蛋白凝胶。令人惊讶的是,His变体的凝血能力大幅降低,且未形成纤维蛋白凝胶。我们的数据表明,这些取代改变了原纤维的形成和横向聚集,这表明γ链的C末端结构域在两个聚合步骤中均起作用。